PaxMedica (PXMD) Stock Price, News & Analysis

Company Overview

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and mood disorders. Leveraging proprietary formulation technologies, the company seeks to improve the safety, tolerability and dosing convenience of established therapeutic agents. By optimizing drug delivery profiles, PaxMedica aims to address unmet needs in patient populations suffering from serious central nervous system conditions.

The company’s pipeline comprises three programs in various stages of development. Its lead candidate is a long-acting injectable formulation designed to provide sustained plasma levels for the management of schizophrenia. A second program is an extended-release oral therapy targeting major depressive disorder, while a third preclinical program is focused on a novel approach to core behavioral features of autism spectrum disorders. PaxMedica collaborates with academic medical centers and contract research organizations to advance these assets through clinical and preclinical studies.

Founded in 2018 and headquartered in New York City, PaxMedica also maintains research operations in Massachusetts and pursues partnerships in Europe. After its initial public offering in 2021, the company has continued to build a leadership team of seasoned professionals in neuroscience R&D, regulatory affairs and global commercialization. The board of directors consists of industry veterans from the biotechnology and pharmaceutical sectors, guiding the company’s strategic growth and development efforts.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 11,503 shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXMD Stock Analysis - Frequently Asked Questions

When did PaxMedica's stock split?

Shares of PaxMedica reverse split before market open on Tuesday, October 31st 2023.The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did PaxMedica IPO?

PaxMedica (PXMD) raised $9 million in an initial public offering on Friday, August 26th 2022. The company issued 1,600,000 shares at $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO.

How do I buy shares of PaxMedica?

Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PaxMedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PaxMedica investors own include Pfizer (PFE), PayPal (PYPL), Oracle (ORCL), Arista Networks (ANET), Avino Silver & Gold Mines (ASM) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PXMD
• CIK: 1811623
• Web: www.paxmedica.com
• Phone: 914-987-2876
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,167.89%
• Return on Assets: -560.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,312,000
• Free Float: 11,199,000
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: -1.01